August 2, 2022 Bio/Pharma/CRO Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results Read more
July 28, 2022 Bio/Pharma/CRO Clinical Research/Diagn. Roche to present scientific progress across Alzheimer’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting Read more
July 22, 2022 Uncategorized CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss Read more
July 21, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023 Read more
July 21, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022 Read more
July 19, 2022 Acad, Gov/Utilities Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease Read more
July 18, 2022 Clinical Research/Diagn. Product Launch Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus Read more
July 14, 2022 Uncategorized Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer Read more
July 14, 2022 Product Launch New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration Read more
July 11, 2022 Bio/Pharma/CRO Product Launch New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A Read more
